S100B protein as a marker of minimal hepatic encephalopathy
Wojciech Pisarek1, Jakub Jarmołowicz2, Elżbieta Poniewierka1
1Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland.
Introduction:
Minimal hepatic encephalopathy (MHE) is an overlooked impairment of central nervous system function in patients with acute and chronic liver diseases. Its impact on patients' quality of life, prognosis, and the incidence of overt hepatic encephalopathy has been proven. Due to diagnostic difficulties, searching for a serum biomarker for MHE appears to be extremely important.
Aim:
The aim of the study was to demonstrate a potential correlation between the serum levels of SB100P protein in patients with MHE symptoms and the levels of SB100P protein in patients with MHE.
Material And Methods:
Given the association of hepatic encephalopathy with central nervous system damage, the study used the serum level of S100B protein in patients diagnosed with MHE based on the Psychometric Hepatic Encephalopathy Score (PHES) test.
Results:
The study results showed a statistically significant correlation between the serum S100B protein level and the PHES test result. It was also found that the S100B protein level was higher than the norm for the healthy population, as provided by the test manufacturer, in 83% of the patients.
Conclusions:
These results are promising, suggesting that further research is needed to verify the significance of S100B protein as a biomarker for MHE.
Insights
Serum S100B protein levels correlate with minimal hepatic encephalopathy (MHE) symptoms. Elevated S100B protein was observed in most MHE patients, suggesting its potential as a diagnostic biomarker.
Area of Science:
- Neurology
- Hepatology
- Biochemistry
Background:
- Minimal hepatic encephalopathy (MHE) is a central nervous system impairment in liver disease patients.
- MHE significantly impacts quality of life and prognosis, often preceding overt hepatic encephalopathy.
- Diagnostic challenges highlight the need for reliable serum biomarkers for MHE.
Purpose of the Study:
- To investigate the correlation between serum S100B protein levels and MHE.
- To assess the potential of S100B protein as a biomarker for MHE diagnosis.
Main Methods:
- Serum S100B protein levels were measured in patients diagnosed with MHE.
- Diagnosis of MHE was confirmed using the Psychometric Hepatic Encephalopathy Score (PHES) test.
Main Results:
- A statistically significant correlation was found between serum S100B protein levels and PHES test results.
- Elevated serum S100B protein levels, above the healthy population norm, were detected in 83% of MHE patients.
Conclusions:
- Serum S100B protein shows a promising correlation with MHE.
- Further research is warranted to validate S100B protein as a specific biomarker for MHE.
More Related Videos
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
